Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia

NCT04979052 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT04979052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04979052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2022
Completion date
March 30, 2026
Enrollment
65 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia